Core Points - Zelluna ASA held its extraordinary general meeting on November 25, 2025, where all agenda items were approved [1] - The minutes from the meeting are available on the company's website [1] Company Information - The meeting was attended by key executives including Anders Tuv (Chairman), Namir Hassan (CEO), and Hans Vassgård Eid (CFO) [1] - Contact information for the executives is provided for further inquiries [1]

Group 1 - Zelluna ASA successfully completed a private placement of 5,500,000 new shares, consisting of a first tranche of 3,729,774 shares and a second tranche of 1,770,226 shares, along with 315,639 shares allocated in a retail offering [1] - The share capital increase related to the issuance of 4,045,413 new shares has been registered, resulting in a new share capital of NOK 24,499,575, divided into 24,499,575 shares with a par value of NOK 1 each [2] Group 2 - Zelluna ASA is a biotechnology company focused on developing allogeneic 'off-the-shelf' T Cell Receptor-based Natural Killer (TCR-NK) cells for cancer treatment, combining NK cells' innate killing power with TCRs' precision targeting [3] - The company's lead program, ZI-MA4-1, targets the MAGE-A4 tumour antigen and is expected to enter clinical trials in 2026 [3]

Group 1 - The company announced a successful private placement and retail offering on 3 November 2025 [1] - An extraordinary general meeting (EGM) is scheduled for 25 November 2025 to discuss proposals for issuing new shares in tranche 2 of the private placement [2] - The EGM will be held electronically, with participation details provided through a specific login link [3] Group 2 - All relevant documents and appendices for the EGM are available on the company's website [3] - Contact information for the CEO and CFO of the company is provided for further inquiries [3]

Group 1 - The company, Zelluna ASA, has announced a private placement of 5,500,000 new shares, which includes a first tranche of 3,729,774 shares and a second tranche of 1,770,226 shares, along with a retail offering of 315,639 shares via the PrimaryBid Platform [1] - Radforsk Investeringsstiftelse holds 2,469,693 shares, representing 12.07% of the total shares and votes in the company, but will temporarily fall below the 10% threshold due to a share lending agreement related to the private placement and retail offering [2] - After the issuance of 4,045,413 new shares in the first tranche and retail offering, Radforsk will regain its original shareholding of 2,469,693 shares, which will then represent 10.08% of the total shares and votes in the company [3]

Core Viewpoint - Zelluna ASA's shares will be traded from November 4, 2025, without the right to participate in the subsequent offering announced on November 3, 2025 [1] Group 1 - The trading of Zelluna ASA shares will exclude participation rights in the upcoming offering [1] - This announcement complies with the Continuing Obligations for Euronext Oslo Børs [1]

Group 1 - The company announced a private placement of 5,500,000 new shares and a retail offering of 315,639 new shares via the PrimaryBid platform on 3 November 2025 [1] - A potential subsequent offering of up to 800,000 new shares at the same subscription price as the private placement and PrimaryBid offering is planned, directed towards existing shareholders who meet specific criteria [1] - The subsequent offering is contingent upon the completion of the private placement, board approval, and an extraordinary general meeting, with the subscription price set at NOK 10 per share [2] Group 2 - Key dates for the subsequent offering include the announcement on 3 November 2025, the last day including rights on the same date, the ex-date on 4 November 2025, and the record date on 5 November 2025 [2] - The maximum number of new shares available in the subsequent offering is 800,000, and the rights will not be listed [2] - The company reserves the right to cancel the subsequent offering based on the share price development after the private placement [2]

Group 1 - The article discusses the private placement and retail offering announced by Zelluna ASA on November 3, 2025 [1] - It mentions the allocation of shares in the Private Placement and share lending to facilitate settlement of tranche 1 of both the Private Placement and the PrimaryBid Offering [1]

Core Insights - Zelluna ASA has successfully raised NOK 58 million to advance its TCR-NK therapy, ZI-MA4-1, into Phase I clinical trials for treating solid cancers [1][2][4] - The financing was strongly supported by existing shareholders and management, indicating confidence in the potential of Zelluna's TCR-NK platform [3][6] - The company aims to deliver a new generation of allogeneic "off-the-shelf" cell therapies, combining T-cell receptors with natural killer cells to enhance treatment efficacy [4][5] Financial Details - The private placement raised NOK 55 million through the allocation of 5,500,000 shares at NOK 10 per share, with an additional NOK 3.16 million raised from the PrimaryBid Offering [8][9] - The net proceeds will be utilized to initiate the Phase I clinical trial, develop the pipeline, and for general corporate purposes [9] Shareholder Engagement - The financing reflects strong investor confidence, with participation from both existing and new investors, showcasing a commitment to Zelluna's vision and scientific approach [5][6] - A subsequent repair offering of up to 800,000 new shares is planned to mitigate dilution effects for existing shareholders not participating in the private placement [18] Clinical Development - The company is positioned to initiate its first clinical study with the world's first MAGE-A4-targeting TCR-NK therapy, which could significantly impact treatment for solid tumors [4][5] - The successful financing marks a pivotal milestone in Zelluna's journey from innovation to clinical validation, with a focus on scalable "off-the-shelf" cell therapies [4][6]

Core Viewpoint - Zelluna ASA is planning a private placement of NOK 50-55 million and a retail offering to fund the initiation of a Phase I clinical trial for its TCR-NK therapy, ZI-MA4-1, aimed at treating cancer, with patient data expected by mid-2026 [1] Private Placement Details - The private placement will issue new shares at an offer price of NOK 10 per share, with a total gross proceeds target of NOK 50-55 million [3][5] - Existing shareholders have pre-committed to subscribe for NOK 50.7 million in shares [2] - The bookbuilding period for the private placement starts on 3 November 2025 and ends on 4 November 2025 [4] Use of Proceeds - Net proceeds from the private placement and retail offering will be allocated to initiate the Phase I clinical trial, develop the pipeline, and cover general corporate purposes [2] Retail Offering - The retail offering, through PrimaryBid, aims to raise up to the NOK equivalent of EUR 1 million, targeting retail investors in Norway [1][16] - The application period for the PrimaryBid Offering is from 3 November 2025 at 16:30 (CET) to 3 November 2025 at 21:00 (CET) [21] Settlement and Allocation - Settlement for the private placement is expected to occur in two tranches, with Tranche 1 anticipated around 6 November 2025 [8][9] - The allocation of shares will be determined by the Board in consultation with the Manager after the application period ends [20] Company Overview - Zelluna ASA focuses on developing "off-the-shelf" T cell receptor (TCR) guided natural killer (NK) cell therapies for advanced solid cancers, aiming to provide safe and cost-effective treatments globally [24]

Core Insights - Zelluna has announced its third quarter 2025 results, highlighting significant advancements in its clinical development and financial status [1][6]. Business Update - Positive feedback was received from the UK's Medicines and Healthcare products Regulatory Agency (MHRA), aligning the clinical strategy for ZI-MA4-1 and supporting the upcoming Clinical Trial Application (CTA) submission [2]. - Preparations for the first-in-human trial of ZI-MA4-1 are progressing, with leading UK cancer centres engaged and a proposed Chief Investigator appointed [3]. - GMP manufacturing of clinical material for the planned Phase I trial was initiated in July 2025, marking a key step in clinical readiness [4]. - A strategic acquisition during Q3 expanded Zelluna's pipeline with a portfolio of TCRs targeting KKLC1, complementing existing targets and broadening patient reach [5]. Financial Highlights - Total operating expenses for Q3 2025 were MNOK 39.7, with a year-to-date total of MNOK 101.0. The total loss for the period was MNOK 39.3, and year-to-date loss was MNOK 98.7 [7]. - Net negative cash flow from operations was MNOK 29.0 in Q3 2025, with a net decrease in cash and cash equivalents of MNOK 28.9 during the same period. Cash and cash equivalents stood at MNOK 47.2 as of 30 September 2025, expected to provide a financial runway into Q2 2026 [7].